Skip to main content

Table 2 Baseline, follow-up and absolute changes (from baseline) for serum creatinine, eGFR, urine NGAL and delta of urine NGAL in each group of all patients (2A), CKD stage III (2B) and CKD stage IV (2C)

From: Urinary Neutrophil Gelatinase-Associated Lipocalin predicts the severity of contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures

2A
Characteristic All patients
No CI-AKI CI-AKI CI-AKI (S1) CI-AKI (S2)
( N = 114) (N = 16) (N = 13) (N = 3)
Serum creatinine (mg/dL)  
Baseline 1.4 ± 0.4 2.0 ± 0.6a 2.0 ± 0.6a 1.9 ± 0.3a
Follow-up (48 hr after) 1.3 ± 0.4 3.1 ± 1.1a 2.7 ± 1.1a 4.5 ± 0.4a,b
Absolute change 0.0 ± 0.2 1.1 ± 0.9a 0.7 ± 0.9a 2.7 ± 0.6a,b
eGFR (ml/min)  
Baseline 44 ± 16 27 ± 7a 27 ± 8a 28 ± 3a
Follow-up (48 hr after) 45 ± 17 18 ± 6a 20 ± 6a 11 ± 2a,b
Absolute change 1 ± 5 -9 ± 5a -7 ± 3a -17 ± 2a,b
Urine NGAL (ng/ml)  
Baseline 68 ± 99 144 ± 111a 154 ± 143a 113 ± 45a
3 h 79 ± 102 211 ± 120a 213 ± 159a 202 ± 60a
6 h 93 ± 129 267 ± 153a 255 ± 191a 316 ± 86a
12 h 115 ± 166 277 ± 169a 256 ± 181a 352 ± 133a
18 h 132 ± 175 298 ± 171a 315 ± 187a 272 ± 80a
24 h 122 ± 165 294 ± 162a 314 ± 173a 265 ± 52a
Delta urine NGAL (ng/ml)  
0-3 h 10 ± 92 66 ± 78a 59 ± 81a 99 ± 61a
0-6 h 24 ± 110 122 ± 87a 101 ± 72a 213 ± 101a,b
0-12 h 42 ± 158 132 ± 91a 112 ± 76a 242 ± 104a,b
0-18 h 59 ± 142 135 ± 136a 137 ± 147a 159 ± 95a
0-24 h 49 ± 149 149 ± 136a 160 ± 136a 151 ± 80a
2B
Characteristic CKD stage III
  No CI-AKI) CI-AKI CI-AKI (S1) CI-AKI (S2)
(N = 90 (N = 10) (N = 9) (N = 1)
Serum creatinine (mg/dL)     
Baseline 1.3 ± 0.3 1.5 ± 0.5 1.5 ± 0.7 1.6
Follow-up (48 hr after) 1.2 ± 0.3 2.7 ± 1.0a 2.5 ± 0.9a 4.6a,b
Absolute change -0.1 ± 0.2 1.1 ± 0.8a 0.9 ± 0.3a 3.0a,b
eGFR (ml/min)     
Baseline 46 ± 14 44 ± 9 43 ± 9 43
Follow-up (48 hr after) 48 ± 11 22 ± 8a 24 ± 8a 14a,b
Absolute change 1 ± 6 -22 ± 9a -18 ± 6a -29a,b
Urine NGAL (ng/ml)     
Baseline 61 ± 81 72 ± 45 75 ± 42 98
3 h 75 ± 83 145 ± 73a 136 ± 72a 220a
6 h 84 ± 119 171 ± 75a 160 ± 70a 264a
12 h 113 ± 162 181 ± 86a 178 ± 78a 208a
18 h 121 ± 161 205 ± 210a 203 ± 79a 226a
24 h 114 ± 163 210 ± 87a 210 ± 93a 204a
Delta of urine NGAL (ng/ml)     
0-3 h 13 ± 80 63 ± 42a 62 ± 64a 122a
0-6 h 22 ± 104 89 ± 87a 85 ± 86a 166a
0-12 h 49 ± 136 99 ± 91a 103 ± 63a 110a
0-18 h 54 ± 131 124 ± 136a 128 ± 55a 128a
0-24 h 46 ± 143 128 ± 136a 135 ± 82a 106a
2C
Characteristic CKD stage IV
  No CI-AKI CI-AKI CI-AKI (S1) CI-AKI (S2)
(N = 24) (N = 6) (N = 4) (N = 2)
Serum creatinine (mg/dL)     
Baseline 1.7 ± 0.5 2.4 ± 0.6a 2.3 ± 0.6a 2.5 ± 0.3a
Follow-up (48 hr after) 1.6 ± 0.6 3.3 ± 1.3a 2.9 ± 0.9a 4.5 ± 0.6a,b
Absolute change -0.1 ± 0.3 1.0 ± 1.2a 0.6 ± 0.4a 2.1 ± 0.8a,b
eGFR (ml/min)     
Baseline 27 ± 3 20 ± 4a 21 ± 5a 19 ± 3a
Follow-up (48 hr after) 27 ± 4 14 ± 6a 15 ± 8a 9 ± 4a,b
Absolute change 0 ± 3 -7 ± 6a -6 ± 4a -10 ± 4a,b
Urine NGAL (ng/ml)     
Baseline 102 ± 98 217 ± 180a 216 ± 231a 218 ± 145a
3 h 116 ± 157 314 ± 251a 340 ± 318a 261 ± 153a
6 h 134 ± 162 404 ± 227a 444 ± 280a 324 ± 124a
12 h 132 ± 191 409 ± 192a 415 ± 239a 396 ± 107a
18 h 193 ± 230 394 ± 221a 348 ± 226a 349 ± 169a
24 h 164 ± 182 385 ± 216a 362 ± 131a 329 ± 148a
Delta of urine NGAL (ng/ml)     
0-3 h 10 ± 156 97 ± 92a 124 ± 106a 84 ± 138a
0-6 h 33 ± 131 187 ± 103a 227 ± 101a 217 ± 159a
0-12 h 20 ± 227 192 ± 108a 198 ± 108a 248 ± 152a
0-18 h 62 ± 186 112 ± 208a 132 ± 112a 162 ± 183a,
0-24 h 63 ± 174 168 ± 212a 145 ± 110a 212 ± 192a,
  1. eGFR indicates estimated glomerular filtration rate.
  2. a P <0.05 compared with No-CI-AKI.
  3. b P <0.05 compared with CI-AKI (S1).